| Literature DB >> 31523008 |
Saara Forsström1, Christopher B Jackson1, Christopher J Carroll2, Mervi Kuronen1, Eija Pirinen3, Swagat Pradhan1, Anastasiia Marmyleva1, Mari Auranen4, Iida-Marja Kleine1, Nahid A Khan1, Anne Roivainen5, Päivi Marjamäki6, Heidi Liljenbäck5, Liya Wang7, Brendan J Battersby8, Uwe Richter8, Vidya Velagapudi9, Joni Nikkanen1, Liliya Euro1, Anu Suomalainen10.
Abstract
Mitochondrial dysfunction elicits stress responses that safeguard cellular homeostasis against metabolic insults. Mitochondrial integrated stress response (ISRmt) is a major response to mitochondrial (mt)DNA expression stress (mtDNA maintenance, translation defects), but the knowledge of dynamics or interdependence of components is lacking. We report that in mitochondrial myopathy, ISRmt progresses in temporal stages and development from early to chronic and is regulated by autocrine and endocrine effects of FGF21, a metabolic hormone with pleiotropic effects. Initial disease signs induce transcriptional ISRmt (ATF5, mitochondrial one-carbon cycle, FGF21, and GDF15). The local progression to 2nd metabolic ISRmt stage (ATF3, ATF4, glucose uptake, serine biosynthesis, and transsulfuration) is FGF21 dependent. Mitochondrial unfolded protein response marks the 3rd ISRmt stage of failing tissue. Systemically, FGF21 drives weight loss and glucose preference, and modifies metabolism and respiratory chain deficiency in a specific hippocampal brain region. Our evidence indicates that FGF21 is a local and systemic messenger of mtDNA stress in mice and humans with mitochondrial disease.Entities:
Keywords: FGF21; de novo serine biosynthesis; endocrine signaling; mitochondrial disease; mitochondrial integrated stress response; mitochondrial unfolded protein response; one carbon cycle; stress response
Year: 2019 PMID: 31523008 DOI: 10.1016/j.cmet.2019.08.019
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287